Raxibacumab is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Attributes | Values |
---|---|
rdf:type |
|
rdfs:label |
|
rdfs:comment |
|
dct:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
ATC suffix |
|
ATC prefix |
|
c |
|
CAS number |
|
ChemSpiderID |
|
DrugBank |
|
H |
|
n |
|
O |
|
s |
|
source |
|
target |
|
type |
|
UNII |
|
Verifiedfields |
|
verifiedrevid |
|
Watchedfields |
|
has abstract |
|
mab type |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
DrugBank |
|
FDA UNII code |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |